JP2015517496A - バイオフィルム形成を防止する方法 - Google Patents

バイオフィルム形成を防止する方法 Download PDF

Info

Publication number
JP2015517496A
JP2015517496A JP2015511575A JP2015511575A JP2015517496A JP 2015517496 A JP2015517496 A JP 2015517496A JP 2015511575 A JP2015511575 A JP 2015511575A JP 2015511575 A JP2015511575 A JP 2015511575A JP 2015517496 A JP2015517496 A JP 2015517496A
Authority
JP
Japan
Prior art keywords
antibody
pnag
seq
domain
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015511575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517496A5 (enExample
Inventor
ジェレミー・イェソン
アストリッド・レイ
シルヴィ・ルフォー
ローラン・フレイス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority claimed from PCT/US2013/039724 external-priority patent/WO2013169657A1/en
Publication of JP2015517496A publication Critical patent/JP2015517496A/ja
Publication of JP2015517496A5 publication Critical patent/JP2015517496A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
JP2015511575A 2012-05-07 2013-05-06 バイオフィルム形成を防止する方法 Pending JP2015517496A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261643650P 2012-05-07 2012-05-07
US61/643,650 2012-05-07
FR1352399 2013-03-18
FR1352399 2013-03-18
PCT/US2013/039724 WO2013169657A1 (en) 2012-05-07 2013-05-06 Methods for preventing biofilm formation

Publications (2)

Publication Number Publication Date
JP2015517496A true JP2015517496A (ja) 2015-06-22
JP2015517496A5 JP2015517496A5 (enExample) 2016-06-23

Family

ID=52691156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511575A Pending JP2015517496A (ja) 2012-05-07 2013-05-06 バイオフィルム形成を防止する方法

Country Status (2)

Country Link
US (1) US20150086601A1 (enExample)
JP (1) JP2015517496A (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11597774B2 (en) 2017-05-04 2023-03-07 City Of Hope Antibody variable domains and antibody constructs
CN114845731A (zh) * 2019-11-22 2022-08-02 阿洛珀希有限公司 针对包含pnag的微生物提供连续治疗的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501317A (ja) * 2004-04-21 2008-01-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ポリ−Ｎ−アセチルグルコサミン（ＰＮＡＧ／ｄＰＮＡＧ）結合ペプチドおよびその使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501317A (ja) * 2004-04-21 2008-01-24 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ポリ−Ｎ−アセチルグルコサミン（ＰＮＡＧ／ｄＰＮＡＧ）結合ペプチドおよびその使用方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GENBANK DATABASES, NCBI. ACCESSION NO.DQ231549, vol. [online], JPN6017000939, 9 May 2006 (2006-05-09), pages 29 - 1, ISSN: 0003480782 *
GENBANK DATABASES, NCBI. ACCESSION NO.DQ231550, vol. [online], JPN6017000942, 9 May 2006 (2006-05-09), pages 29 - 1, ISSN: 0003480783 *
ＩＮＦＥＣＴＩＯＮ ＡＮＤ ＩＭＭＵＮＩＴＹ, vol. 74, no. 5, JPN6017000933, 2006, pages 2742 - 2750, ISSN: 0003480779 *
ＩＮＦＥＣＴＩＯＮ ＡＮＤ ＩＭＭＵＮＩＴＹ, vol. 75, no. 7, JPN6017000930, 2007, pages 3406 - 3413, ISSN: 0003480778 *
ＪＯＵＲＮＡＬ ＯＦ ＩＮＦＥＣＴＩＯＵＳ ＤＩＳＥＡＳＥＳ, vol. 192, no. 11, JPN6017000935, 2005, pages 2012 - 2019, ISSN: 0003480780 *
信州医学雑誌, vol. 53, no. 2, JPN6017000937, 2005, pages 91 - 92, ISSN: 0003480781 *

Also Published As

Publication number Publication date
US20150086601A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
TWI591074B (zh) ＰＤＧＦ受體β結合多肽
KR102115438B1 (ko) 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
US9376494B2 (en) Antibodies to kallidin and des-Arg9-kallidin
TW201801743A (zh) 低親和力血腦障壁受體抗體及其用途
ES2800674T3 (es) Polipéptidos biespecíficos de unión a antígeno
JP2026054439A (ja) 化学療法または放射線療法で誘導された好中球減少症を治療する方法
KR102120620B1 (ko) 면역글로불린을 이용한 점막염의 치료
US20150086601A1 (en) Methods for preventing biofilm formation
WO2013169657A1 (en) Methods for preventing biofilm formation
JP2026510595A (ja) サシツズマブ薬物複合体及びその調製
JP2019505516A (ja) インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
US20150210755A1 (en) Anti-poly-n-acetyl glucosamine (pnag) monoclonal antibody and uses thereof for the prevention or treatment of pnag expressing bacterial infection
HK1259793B (en) Methods for improving safety of blood-brain barrier transport
HK1202882B (en) Pdgf receptor beta binding polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180109